If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
EMGALITY® (galcanezumab-gnlm): Metabolism and Elimination
Emgality (galcanezumab) is expected to be degraded via catabolic pathways in the same manner as endogenous IgG.
As such, it is not expected to
inhibit metabolic or induce enzymatic pathways
be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
Enclosed Prescribing Information
2. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
4. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178
CL/F = apparent clearance
IgG = immunoglobulin G
IgG4 = immunoglobulin G (subclass) 4
Date of Last Review: July 22, 2020